UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 64

Sortiert nach

Neurocognitive functions and health‐related quality of life in glioblastoma patients: a concise review of the literature

European journal of cancer care, 2019-01, Vol.28 (1), p.e12410-n/a

2019

Volltextzugriff (PDF)

Cognitive Rehabilitation in Patients with Gliomas and Other Brain Tumors: State of the Art

BioMed research international, 2016-01, Vol.2016, p.3041824-11

2016

Volltextzugriff (PDF)

Comprehensive geriatric assessment (CGA) for outcome prediction in elderly patients (PTS) with glioblastoma (GBM): A mono-institutional experience

Annals of oncology, 2018-10, Vol.29, p.viii125-viii125

2018

Volltextzugriff (PDF)

Suspicious for recurrent low and high grade glioma and indeterminate MRI: the role of 18F-DOPA PET/CT

Annals of oncology, 2017-10, Vol.28, p.vi76-vi77

2017

Volltextzugriff (PDF)

2921 Low-dose Fotemustine in elderly patients with recurrent glioblastoma: A phase II prospective study

European journal of cancer (1990), 2015-09, Vol.51, p.S591-S591

2015

Volltextzugriff (PDF)

Worsening of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) can predict radiologic progressive disease (RPD) in glioblastoma (GBM) patients (PTS) treated with radiation therapy (RT) and temozolomide (TMZ): a mono-institutional prospective study

Annals of oncology, 2017-10, Vol.28, p.vi76-vi76

2017

Volltextzugriff (PDF)

Mismatch repair deficiency (MMRd) in glioma patients (PTS): Frequency and correlation with clinical, histological and molecular characteristics

Annals of oncology, 2018-10, Vol.29, p.viii123-viii123

2018

Volltextzugriff (PDF)

2916 A prospective study analyzing quality of life and cognitive function in patients with glioblastoma treated with RT and Temozolomide: Impact of age and gender

European journal of cancer (1990), 2015-09, Vol.51, p.S590-S590

2015

Volltextzugriff (PDF)

P17.53 THE COMBINATION OF CARMUSTINE WAFERS AND FOTEMUSTINE IN RECURRENT GLIOBLASTOMA PATIENTS: OUR EXPERIENCE

Neuro-oncology (Charlottesville, Va.), 2014-09, Vol.16 (suppl 2), p.ii99-ii100

2014

Volltextzugriff (PDF)

Effectiveness of antiangiogenic drugs (ADs) in glioblastoma (GBM) patients (PTS): a metanalysis of randomized clinical trials (RCTs)

Annals of oncology, 2016-10, Vol.27, p.vi104-vi104

2016

Volltextzugriff (PDF)

Effectiveness of antiangiogenic drugs (ADs) in glioblastoma (GBM) patients (PTS): a metanalysis of randomized clinical trials (RCTs)

Annals of oncology, 2016-09, Vol.27, p.iv107

2016

Volltextzugriff (PDF)

1273P Early integration between oncologic treatment and palliative care: Experience of the simultaneous care outpatient clinic at Veneto Institute of Oncology, ESMO Designated Center

Annals of oncology, 2022-09, Vol.33, p.S1128-S1129

2022

Volltextzugriff (PDF)

Alternative schedule of Fotemustine in elderly patients with recurrent glioblastoma: a phase II prospective study

Annals of oncology, 2015-10, Vol.26, p.vi145

2015

Volltextzugriff (PDF)

A prospective analysis of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) in glioblastoma (GBM) patients (PTS) treated with RT and temozolomide (TMZ)

Annals of oncology, 2016-10, Vol.27, p.vi110-vi110

2016

Volltextzugriff (PDF)

A prospective analysis of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) in glioblastoma (GBM) patients (PTS) treated with RT and Temozolomide (TMZ)

Annals of oncology, 2016-09, Vol.27, p.iv116

2016

Volltextzugriff (PDF)

Worsening of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) can predict radiologic progressive disease (RPD) in glioblastoma (GBM) patients (PTS) treated with radiation therapy (RT) and temozolomide (TMZ): A mono-institutional prospective study

Annals of oncology, 2017-09, Vol.28, p.v119-v119

2017

Volltextzugriff (PDF)

P01.021 Comprehensive Geriatric Assessment (CGA) for outcome prediction in elderly patients (PTS)with glioblastoma (GBM): a mono-institutional experience

Neuro-oncology (Charlottesville, Va.), 2018-09, Vol.20 (suppl_3), p.iii232-iii233

2018

Volltextzugriff (PDF)

Anaplastic astrocytoma (AA) and glioblastoma (GBM): a real-life experience in Padua Neuro-Oncology Center

Annals of oncology, 2016-10, Vol.27, p.vi111-vi111

2016

Volltextzugriff (PDF)

Anaplastic Astrocytoma (AA) and Glioblastoma (GBM): a real-life experience in Padua

Annals of oncology, 2016-09, Vol.27, p.iv114

2016

Volltextzugriff (PDF)

Activity of temozolomide (TMZ) in patients (PTS) with malignant pheochromocytoma or paraganglioma (MPP): A mono-institutional retrospective study

Annals of oncology, 2017-09, Vol.28, p.v156-v156

2017

Volltextzugriff (PDF)

P01.018 Mismatch repair deficiency (MMRd) in glioma patients (PTS): frequency and correlation with clinical, histological and molecular characteristics

Neuro-oncology (Charlottesville, Va.), 2018-09, Vol.20 (suppl_3), p.iii232-iii232

2018

Volltextzugriff (PDF)

P09.29 Anaplastic Astrocytoma (AA) and Glioblastoma (GBM): a real-life experience in Padua Neuro-Oncology Center

Neuro-oncology (Charlottesville, Va.), 2017-05, Vol.19 (suppl_3), p.iii76-iii76

2017

Volltextzugriff (PDF)

MGMT promoter methylation status in glioblastoma (GBM) patients: a quantitative pyrosequencing approach and its prognostic role

Annals of oncology, 2016-10, Vol.27, p.vi107-vi107

2016

Volltextzugriff (PDF)

MGMT promoter methylation status in glioblastoma (GBM) patients: a quantitative pyrosequencing approach and its prognostic role

Annals of oncology, 2016-09, Vol.27, p.iv114

2016

Volltextzugriff (PDF)

REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib activity in relapsed glioblastoma patients

Annals of oncology, 2017-09, Vol.28, p.v610-v610

2017

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(59)
Mit Volltextzugriff
(63)

Publikationsform

Sprache

Englisch
(64)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Neurocognitive functions and health‐related quality of life in glioblastoma patients: a concise review of the literature

Cognitive Rehabilitation in Patients with Gliomas and Other Brain Tumors: State of the Art

Comprehensive geriatric assessment (CGA) for outcome prediction in elderly patients (PTS) with glioblastoma (GBM): A mono-institutional experience

Suspicious for recurrent low and high grade glioma and indeterminate MRI: the role of 18F-DOPA PET/CT

2921 Low-dose Fotemustine in elderly patients with recurrent glioblastoma: A phase II prospective study

Worsening of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) can predict radiologic progressive disease (RPD) in glioblastoma (GBM) patients (PTS) treated with radiation therapy (RT) and temozolomide (TMZ): a mono-institutional prospective study

Mismatch repair deficiency (MMRd) in glioma patients (PTS): Frequency and correlation with clinical, histological and molecular characteristics

2916 A prospective study analyzing quality of life and cognitive function in patients with glioblastoma treated with RT and Temozolomide: Impact of age and gender

P17.53 THE COMBINATION OF CARMUSTINE WAFERS AND FOTEMUSTINE IN RECURRENT GLIOBLASTOMA PATIENTS: OUR EXPERIENCE

Effectiveness of antiangiogenic drugs (ADs) in glioblastoma (GBM) patients (PTS): a metanalysis of randomized clinical trials (RCTs)

Effectiveness of antiangiogenic drugs (ADs) in glioblastoma (GBM) patients (PTS): a metanalysis of randomized clinical trials (RCTs)

1273P Early integration between oncologic treatment and palliative care: Experience of the simultaneous care outpatient clinic at Veneto Institute of Oncology, ESMO Designated Center

Alternative schedule of Fotemustine in elderly patients with recurrent glioblastoma: a phase II prospective study

A prospective analysis of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) in glioblastoma (GBM) patients (PTS) treated with RT and temozolomide (TMZ)

A prospective analysis of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) in glioblastoma (GBM) patients (PTS) treated with RT and Temozolomide (TMZ)

Worsening of quality of life (QoL), cognitive functions (CF) and psychological status (PSY) can predict radiologic progressive disease (RPD) in glioblastoma (GBM) patients (PTS) treated with radiation therapy (RT) and temozolomide (TMZ): A mono-institutional prospective study

P01.021 Comprehensive Geriatric Assessment (CGA) for outcome prediction in elderly patients (PTS)with glioblastoma (GBM): a mono-institutional experience

Anaplastic astrocytoma (AA) and glioblastoma (GBM): a real-life experience in Padua Neuro-Oncology Center

Anaplastic Astrocytoma (AA) and Glioblastoma (GBM): a real-life experience in Padua

Activity of temozolomide (TMZ) in patients (PTS) with malignant pheochromocytoma or paraganglioma (MPP): A mono-institutional retrospective study

P01.018 Mismatch repair deficiency (MMRd) in glioma patients (PTS): frequency and correlation with clinical, histological and molecular characteristics

P09.29 Anaplastic Astrocytoma (AA) and Glioblastoma (GBM): a real-life experience in Padua Neuro-Oncology Center

MGMT promoter methylation status in glioblastoma (GBM) patients: a quantitative pyrosequencing approach and its prognostic role

MGMT promoter methylation status in glioblastoma (GBM) patients: a quantitative pyrosequencing approach and its prognostic role

REGOMA: A randomized, multicenter, controlled open-label phase II clinical trial evaluating regorafenib activity in relapsed glioblastoma patients

Suchergebnisse filtern